Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Opole – page 11

140 clinical trials in Opole, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Opole at a glance
140
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

140 trials in Opole

Open in trial search

Diffuse large B-cell lymphoma recurrent

Not recruiting

Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Diffuse large B-cell lymphoma

Not recruiting

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Systemic lupus erythematosus+3

Not recruiting

Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Myelofibrosis

Not recruiting

Study on Extended Access to Momelotinib for Patients with Myelofibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AudioCure Pharma GmbH

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Sapablursen for Patients with Phlebotomy Dependent Polycythemia Vera

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Ionis Pharmaceuticals Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Opole

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure treatments, including investigations of medications like sacubitril/valsartan for various cardiac conditions. Research encompasses both acute and chronic heart conditions.

  • Heart Failure Management
  • Cardiogenic Shock Treatment
  • Post-Infarction Care

Multiple trials exploring treatments for patients with reduced ejection fraction and acute cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, with particular focus on breast cancer and prostate cancer treatments. Studies evaluate novel therapeutic approaches and drug combinations.

  • Metastatic Cancer Treatments
  • Targeted Therapies
  • Colorectal Cancer Research

Investigations include both early-stage and advanced cancer treatments using innovative therapeutic agents.

03 Immunology and Inflammation

Studies examining treatments for autoimmune conditions and inflammatory disorders, including research on novel therapies for psoriatic arthritis and urticaria.

  • Arthritis Management
  • Inflammatory Bowel Disease
  • Immune System Disorders

Clinical investigations focus on improving patient outcomes through targeted immunological interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.